Related Experiment Video

Updated: Aug 18, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality

Bac Viet Le1,2, Paulina Podszywałow-Bartnicka2, Katarzyna Piwocka2

  • 1Fels Cancer Institute for Personalized Medicine, Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.

Cancers
|December 11, 2022
PubMed

Insights

Synthetic lethality, using Poly (ADP-ribose) polymerase inhibitors (PARPi), shows promise in cancer treatment. Understanding and overcoming PARPi resistance mechanisms is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Synthetic lethality offers targeted cancer therapies, with Poly (ADP-ribose) polymerase inhibitors (PARPi) being a key approach.
  • PARPi are effective against homologous recombination-defective tumors and certain leukemias.
  • Resistance to PARPi, both pre-existing and acquired, limits treatment efficacy.

Purpose of the Study:

  • To elucidate the mechanisms underlying Poly (ADP-ribose) polymerase inhibitor resistance.
  • To explore how the bone marrow microenvironment contributes to pre-existing resistance.
  • To identify strategies for overcoming Poly (ADP-ribose) polymerase inhibitor resistance in cancer therapy.

Main Methods:

  • Review of existing literature on synthetic lethality and Poly (ADP-ribose) polymerase inhibitor resistance.
  • Analysis of preclinical and clinical data regarding resistance mechanisms.
  • Discussion of potential therapeutic interventions against resistance.

Main Results:

  • Both pre-existing and acquired resistance mechanisms to Poly (ADP-ribose) polymerase inhibitors have been identified.
  • The bone marrow microenvironment plays a role in inducing resistance in leukemic cells.
  • Understanding these mechanisms is essential for developing effective resistance-repressing therapies.

Conclusions:

  • Elucidating Poly (ADP-ribose) polymerase inhibitor resistance mechanisms is critical for advancing personalized cancer medicine.
  • Targeting resistance pathways could enhance the efficacy of Poly (ADP-ribose) polymerase inhibitor-based therapies.
  • Further research is needed to develop novel strategies to prevent or overcome Poly (ADP-ribose) polymerase inhibitor resistance.
Keywords:
DNA repairPARP inhibitorsPARPi resistancebone marrow microenvironmentleukemia cellssynthetic lethality

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.3K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.1K
Translesion DNA Polymerases02:10

Translesion DNA Polymerases

Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
10.1K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.9K